InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (9 ops.)
Browse the full record of transactions filed by Crockett Thomas Andrew, Chief Executive Officer. Director active across 1 companies, notably KalVista Pharmaceuticals, Inc.. Cumulatively, 11 reports have been published. Total volume traded: €1.1m. The latest transaction was disclosed on 9 March 2022 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations11 total
€156,62410,000 shares@ €15.66240.011% mcap13.9% of flow
Common Stock
SEC:0001209191-22-018184:0·
€148,46510,000 shares@ €14.84650.010% mcap30.7% of flow
Common Stock
SEC:0001209191-21-059042·
€148,46510,000 shares@ €14.84650.010% mcap13.2% of flow
Common Stock
SEC:0001209191-21-059042:0·
€87,6844,350 shares@ €20.15720.0062% mcap18.1% of flow
Common Stock
SEC:0001209191-21-045093·
€87,6844,350 shares@ €20.15720.0062% mcap7.8% of flow
Common Stock
SEC:0001209191-21-045093:0·
€26,9031,067 shares@ €25.21360.0019% mcap5.6% of flow
Common Stock
SEC:0001209191-21-042450·
€26,9031,067 shares@ €25.21360.0019% mcap2.4% of flow
Common Stock
SEC:0001209191-21-042450:0·
€220,3918,933 shares@ €24.67160.015% mcap19.6% of flow
Common Stock
SEC:0001209191-21-040040:0·
€220,3918,933 shares@ €24.67160.015% mcap45.6% of flow
Common Stock
SEC:0001209191-21-040040·
04,750 shares0
Common Stock
SEC:0001209191-21-036588·
04,750 shares0
Common Stock
SEC:0001209191-21-036588:0·
11 of 11 declarations
About Crockett Thomas Andrew
Thomas Andrew Crockett is the CEO of KalVista Pharmaceuticals, Inc. He leads the company in developing treatments for rare diseases. Under his leadership, KalVista focuses on innovation and expanding its products in the market.
